𝔖 Bobbio Scriptorium

✦ LIBER ✦

Allergic asthma and an anti-CD23 mAb (IDEC-152) Results of a phase I, single-dose, dose-escalating clinical trial

✍ Scribed by Rosenwasser, L

Book ID: 119491030
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 365 KB
Volume: 112
Category: Article
ISSN: 1097-6825
DOI: 10.1016/s0091-6749(03)01861-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a phase II, multiple-dose, ra

Results of a phase II, multiple-dose, randomized trial of an anti-CD23 monoclonal antibody (IDEC-152) in patients with seasonal allergic rhinitis

✍ Casale, T.B.; Busse, W.W.; Lizambri, R.G.; Korenblat, P.E.; Schoenwetter, W.F.; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Tandem high-dose therapy in relapsed and

Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with131I-anti-CD20 antibody and stem cell rescue

✍ Karin Hohloch; Carsten Oliver Sahlmann; Vijai J. Lakhani; Gerald Wulf; Bertram G 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 233 KB

Immunotherapy with FBTA05 (Bi20), a trif

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

✍ Raymund Buhmann, Stanglmaier Michael, Hess Juergen… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 328 KB